How the Endocannabinoid System Drives Alcohol-Seeking Behavior and Why Blocking CB1 Receptors Reduces Drinking
Evidence from animal studies and human brain imaging shows that chronic alcohol exposure disrupts the endocannabinoid system, and blocking CB1 receptors reduces alcohol consumption, relapse, and dopamine release in reward circuits.
Quick Facts
What This Study Found
This review synthesized evidence showing that the endocannabinoid system plays a central role in alcohol-motivated behavior. Chronic alcohol exposure increases endocannabinoid levels, which in turn downregulates CB1 receptors and uncouples them from their downstream signaling pathways.
In rodent studies, blocking CB1 receptors with rimonabant or genetically deleting them reduced voluntary alcohol drinking, alcohol-triggered dopamine release in the reward center (nucleus accumbens), self-administration of alcohol, and reinstatement/relapse behavior.
PET brain imaging in human alcoholic patients confirmed similar CB1 receptor downregulation across multiple brain regions, suggesting the animal findings translate to humans.
However, rimonabant's psychiatric side effects limit its clinical use. The review highlights two promising alternatives: negative allosteric modulators of CB1 and inhibitors of endocannabinoid breakdown enzymes.
Key Numbers
Chronic alcohol exposure increases endocannabinoid levels in cell culture and rodent models. PET imaging confirms CB1 downregulation in multiple brain regions of human alcoholics. Rimonabant and CB1 genetic deletion reduce alcohol drinking, self-administration, and relapse in rodents.
How They Did This
Narrative review synthesizing preclinical rodent studies, genetic knockout experiments, in vitro cell culture work, and human PET imaging studies examining the relationship between the endocannabinoid system and alcohol-motivated behavior.
Why This Research Matters
Alcohol use disorder is a massive health problem with limited treatment options. The endocannabinoid system represents a validated therapeutic target, and understanding how it drives alcohol-seeking behavior could lead to new medications, particularly if the psychiatric side effects of direct CB1 blockade can be avoided.
The Bigger Picture
The convergence of animal and human data makes the endocannabinoid system one of the more validated targets for alcohol use disorder treatment. The challenge is developing drugs that preserve the therapeutic effects of CB1 modulation while avoiding the depression and anxiety that plagued rimonabant.
What This Study Doesn't Tell Us
Most evidence comes from animal models that may not fully replicate human alcohol use disorder. Rimonabant's clinical failure limits the direct translatability. The newer approaches (allosteric modulators, enzyme inhibitors) remain in early development.
Questions This Raises
- ?Could negative allosteric modulators of CB1 treat alcohol use disorder without psychiatric side effects?
- ?Does the endocannabinoid disruption caused by alcohol contribute to the high rates of cannabis co-use among people with alcohol problems?
Trust & Context
- Key Stat:
- CB1 blockade reduces alcohol drinking, dopamine release, and relapse in animal models
- Evidence Grade:
- Narrative review synthesizing converging evidence from multiple methodologies (cell culture, animal models, human PET imaging), but no new primary data.
- Study Age:
- Published in 2016. Research on peripherally restricted CB1 antagonists and allosteric modulators for addiction has progressed since.
- Original Title:
- Roles for the endocannabinoid system in ethanol-motivated behavior.
- Published In:
- Progress in neuro-psychopharmacology & biological psychiatry, 65, 330-9 (2016)
- Authors:
- Henderson-Redmond, Angela N(4), Guindon, Josée(2), Morgan, Daniel J(4)
- Database ID:
- RTHC-01175
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How does the endocannabinoid system relate to alcohol addiction?
Chronic alcohol increases endocannabinoid levels, downregulates CB1 receptors, and disrupts reward signaling. Blocking CB1 receptors reduces alcohol drinking and relapse in animal studies.
Why not just use a CB1 blocker to treat alcoholism?
The most studied CB1 blocker, rimonabant, caused depression and anxiety in clinical use. Newer approaches like negative allosteric modulators may preserve the anti-alcohol effects without these side effects.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-01175APA
Henderson-Redmond, Angela N; Guindon, Josée; Morgan, Daniel J. (2016). Roles for the endocannabinoid system in ethanol-motivated behavior.. Progress in neuro-psychopharmacology & biological psychiatry, 65, 330-9. https://doi.org/10.1016/j.pnpbp.2015.06.011
MLA
Henderson-Redmond, Angela N, et al. "Roles for the endocannabinoid system in ethanol-motivated behavior.." Progress in neuro-psychopharmacology & biological psychiatry, 2016. https://doi.org/10.1016/j.pnpbp.2015.06.011
RethinkTHC
RethinkTHC Research Database. "Roles for the endocannabinoid system in ethanol-motivated be..." RTHC-01175. Retrieved from https://rethinkthc.com/research/henderson-redmond-2016-roles-for-the-endocannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.